“Although there is probably not a better biotech stock valuation metric than common sense and experience, rNPV (risk adjusted NPV) is a nice way of calculating an order of magnitude for a mid-to late-stage project,” said Jan de Kerpel, Managing Director of Life Sciences & Healthcare at the Dutch bank Kempen Corporate Finance.”
- extract from
https://www.labiotech.eu/expert-advice/biotech-valuation/For those interested in valuation methods for biotechs, see above.
I really like our odds as linked to the listed events in your post,
@dachopper. #77956181. As we all know, they are late-stage, the hard yards have been done.. Speaking from my own past experience managing fund managers and allocating investment capital for retail wealth managers and industry funds, this is exactly what instos, particularly those in the US and including those specialising in techs and biotechs, look for. The interest from institutions and their understanding in the amazing pipeline will build as they start doing more work, much like retail investors have done in the last 2 years.. What they will suddenly realise is that said pipeline is unbelievably rich and diverse, and the company’s understanding of the approval process is now an extra and substantial competitive advantage. Interest in the “cell” in “cell and gene therapies” is really going to be revived and compete well with the gene edited side of the industry. The discount rate for the company will be going through signifcant downward step changes boosting the rNPV in the next 6-18 months.. despite the massive SP returns in the last year.. The latter will ensure near term index entry paves the way for new institutional ownership and a virtuous cycle.
(20min delay)